Journals / Türkiye Çocuk Hastalıkları Dergisi / 2019 / Cilt: 13 - Sayı: 3

Booster Dose Vaccine Response among Children Who were Primary Hepatitis B Vaccine Non-Responders and Sensitive Groups Concerning Vaccine Response

Pages
160–164
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In fact, we believe that 3 dosevaccination is better among those children whose anti-HBs titer is under

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, booster dose vaccine response was evaluated after performing a vaccine schedule at 0,1st and 6th months among 83 children aged between 2 and 16 years who were primary hepatitis B vaccine nonresponders and we tried to determine which groups were sensitive concerning vaccine response.Material and Methods: Euvax B vaccine which included 10 μg HBsAg was administered in 3 doses for the secondtime at 0, 1 and 6 months as 0.5 ml intramuscularly in the deltoid muscle to 83 healthy children aged between 2 and 16years who were primary hepatitis B vaccine non-responders and their vaccine status was determined with tests beforeminor surgery.
📊
Key Findings & Data:Blood tests were taken three times from children at 1, 6 and 7 months after the first vaccination and antiHBs titer was evaluated by using enzyme-linked immunosorbent assay technique.Results: The mean age of the children was 9.3±3.6 years (2-15,9 years).
💡
Conclusion & Impact:In fact, we believe that 3 dosevaccination is better among those children whose anti-HBs titer is under
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, booster dose vaccine response was evaluated after performing a vaccine schedule at 0,1st and 6th months among 83 children aged between 2 and 16 years who were primary hepatitis B vaccine nonresponders and we tried to determine which groups were sensitive concerning vaccine response.Material and Methods: Euvax B vaccine which included 10 μg HBsAg was administered in 3 doses for the secondtime at 0, 1 and 6 months as 0.5 ml intramuscularly in the deltoid muscle to 83 healthy children aged between 2 and 16years who were primary hepatitis B vaccine non-responders and their vaccine status was determined with tests beforeminor surgery. Blood tests were taken three times from children at 1, 6 and 7 months after the first vaccination and antiHBs titer was evaluated by using enzyme-linked immunosorbent assay technique.Results: The mean age of the children was 9.3±3.6 years (2-15,9 years). The anti-HBs geometric mean concentrationwas found to be 537.97±377.51 mIU/mL (0.6-1000) after the first vaccination, as 309.33± 337.45 mIU/mL (8-1000)after the second vaccination and as 609.78±347.43 mIU/mL (11.1-1000) following the third vaccination. Anti-HBspositive conversion rates in T1 were compared in 81 children who had been checked after the first vaccination and antiHBs positive conversion rates were found to be significantly lower in children whose anti-HBs titer was under 1 mlU/mlbefore vaccination (p=0,01, Z -3.29, U 469). There was no difference concerning T6 and T7 between these two groups.Anti-HBs positive conversion rates in T6 and T7 were found to be significantly higher in children with malnutrition(p=0.008, Z -2.56, U 60.5, p=0.03, Z -2.11, U 26.5).Conclusion: When observing the rapid decrease in T6 in contrast with the two dose vaccination, it is thought that antiHBs seroconversion rates and anti-HBs geometric mean concentration are related with reminding, anti-HBs titer beforevaccination and checking time of anti-HBs rather than the number of reminding doses. In fact, we believe that 3 dosevaccination is better among those children whose anti-HBs titer is under

Özet

Amaç: Çalışmada birincil hepatit B aşı yanıtsız 2-16 yaş aralığındaki 83 çocukta, 0, 1 ve 6. ay aşı şeması uygulanarak elde edilen hatırlatma doz aşı yanıtları değerlendirilmiş ve aşı yanıtında hassas gruplar belirlenmeye çalışılmıştır. Gereç ve Yöntemler: Küçük cerrahi girişimler öncesi yapılan tetkikler sonrasında birincil hepatit B aşı yanıtsızlığı saptanan 2-16 yaş aralığındaki sağlıklı 83 çocuğa, 2. kez 0, 1 ve 6. aylarda 3 doz 10 μg HBsAg içeren Euvax B aşısı deltoid kasa 0.5ml kas içine uygulanmıştır. Çocuklardan birinci aşıdan 1, 6 ve 7. ay sonra olmak üzere, 3 kez kan alınarak antiHBs titresi enzyme-linked immunosorbent assay tekniği ile değerlendirilmiştir. Bulgular: Çocukların yaş ortalaması 9.3±3.6 yıl (2-15.9) bulunmuştur. Birinci aşı sonrası anti-HBs ortalama geometrik konsantrasyonu 537.97±377.51 mIU/mL (0.6-1000), 2. aşı sonrası 309.33± 337.45 mIU/mL (8-1000), 3. aşı sonrası 609.78±347.43 mIU/mL (11.1-1000) bulunmuştur. Birinci aşı sonrası tetkik yapılabilen 81 çocuk arasında T1’de antiHBs-positive serokonversiyon oranı, aşı öncesi anti-HBs titresi 1 mIU/mL’nin altında olan çocuklarda diğer gruba göre istatistiksel anlamlı biçimde daha düşük bulunmuştur (p=0.01, Z -3.29, U 469). Bu 2 grup arasında T6 ve T7’de istatistiksel fark saptanmamıştır. Malnütrisyonlu hastalarda T6 ve T7’de anti-HBs positive serokonversiyon oranı diğer gruba göre istatistiksel anlamlı olarak daha yüksek bulunmuştur (p=0.008, Z -2.56, U 60.5, p=0.03, Z -2.11, U 26.5). Sonuç: İki doz aşıya rağmen T6’daki hızlı düşüşe bakıldığında, anti-HBs serokonversiyon oranı ve anti-HBs ortalama geometrik konsantrasyon değerleri hatırlatma doz sayısından ziyade, hatırlatma yapılmasına, aşı öncesi anti-HBs titresine ve anti-HBs titresi bakma zamanıyla ilgili gözükmektedir. Ancak, aşı öncesi anti-HBs titresi

🔖

Cite This Article

ÇAKIR, B. Ç., PARLAKAY, A. Ö., UZUN, A. K., PAKSOY, Z. (2022). Booster Dose Vaccine Response among Children Who were Primary Hepatitis B Vaccine Non-Responders and Sensitive Groups Concerning Vaccine Response. Türkiye Çocuk Hastalıkları Dergisi, Cilt: 13 - Sayı: 3, 160–164. https://ajindex.com/articles/627202

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Immunization Coverage. Availablefrom:http://www.who.int/mediacentre/factsheets/fs378/en/. Accessed date: 1 Haziran, 2016 2. Zhuang GH,Yan H, Wang XL. Risk factors of and mechanism for non-responsiveness to hepatitis B vaccination. Zhonghua Gan Zang Bing Za Zhi 2006
  2. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998
  3. 1–8. 4. http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html (8.5.2017) 5. Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: A systematic review. BMC Infectious Diseases 2011
  4. Bonanni P, Pesavento G, Boccalini S, Bechini A. Perspectives of public health: Present and foreseen impact of vaccination on the epidemiology of hepatitis B. J Hepatol 2003
  5. Ozmert EN. Dünya’da ve Türkiye’de aşılama takvimindeki gelişmeler. Çocuk Sağlığı ve Hastalıkları Dergisi 2008
  6. Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine 2008
  7. Behre U, Bleckmann G, Crasta PD, Leyssen M, Messier M, Jacquet JM. Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination. Hum Vaccin Immunother 2012
  8. Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M. Antibody persistence and the effect of a booster dose given 5, 10 or 15years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine 2013
  9. Fitz Simons D, François G, Hall A, McMahon B, Meheus A, Zanetti A. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005
  10. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine 1996
  11. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004
  12. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccinatio